p27Kip1-deficient mice exhibit accelerated growth hormone-releasing hormone (GHRH)-induced somatotrope proliferation and adenoma formation

p27Kip1 (p27) controls cell cycle progression by binding to and inhibiting the activity of cyclin dependent kinases. Disruption of the p27 gene in mice (p27-/-) results in increased body growth with a disproportionate enlargement of the spleen, thymus, testis, ovary and pituitary. The increase in pi...

Full description

Saved in:
Bibliographic Details
Published inOncogene Vol. 19; no. 15; pp. 1875 - 1884
Main Authors TEIXEIRA, L. T, KIYOKAWA, H, PENG, X. D, CHRISTOV, K. T, FROHMAN, L. A, KINEMAN, R. D
Format Journal Article
LanguageEnglish
Published Basingstoke Nature Publishing 06.04.2000
Nature Publishing Group
Subjects
Online AccessGet full text

Cover

Loading…
Abstract p27Kip1 (p27) controls cell cycle progression by binding to and inhibiting the activity of cyclin dependent kinases. Disruption of the p27 gene in mice (p27-/-) results in increased body growth with a disproportionate enlargement of the spleen, thymus, testis, ovary and pituitary. The increase in pituitary size is due to selective hyperplasia of the intermediate lobe (IL) while the anterior lobe (AL) is not overtly affected. p27 heterozygous mice (p27+/-), as well as p27-/- mice, are hypersensitive to radiation- and chemical-induced tumors compared to wildtype (p27+/+) littermates. Therefore, unlike classical tumor suppressors, only a reduction in p27 levels is necessary to predispose tissues to secondary tumor promoters. Consistent with these studies is the fact that the p27 gene sequence and mRNA levels appear normal in human pituitary adenomas while p27 protein levels are decreased. Therefore, a reduction in p27 levels could be sufficient to sensitize pituitary cells to tumorigenic factors. To test this hypothesis, metallothionein promoter-driven, human growth hormone-releasing hormone (MT-hGHRH) transgenic mice, that exhibit somatotrope hyperplasia before 9 months of age and subsequent adenoma formation with 30 - 40% penetrance, were crossbred with p27+/- mice for two successive generations to produce p27+/+, p27+/- and p27-/- mice that expressed the hGHRH transgene. At 10 - 12 weeks of age, p27-/- and p27+/+, hGHRH mice were larger than their p27+/+ littermates and displayed characteristic hyperplasia of the IL and AL, respectively. Expression of the hGHRH transgene in both p27+/- and p27-/- mice selectively expanded the population of somatotropes within the AL, where pituitaries of p27+/-, hGHRH and p27-/-, hGHRH mice were two- and fivefold larger than p27+/+, hGHRH pituitaries, respectively. There was also a synergistic effect of hGHRH transgene expression and p27-deficiency on liver, spleen and ovarian growth. At 6 - 8 months of age, 83% of p27+/-, hGHRH mice displayed macroscopic AL adenomas (>100 mg), while all pituitaries from p27+/+, hGHRH mice remained hyperplastic (<20 mg). In contrast to the dramatic effects of p27-deficiency on hGHRH-induced organ growth, elimination of p53, by crossbreeding MT-hGHRH mice to p53-deficient mice, did not augment the hyperplastic/tumorigenic effects of hGHRH transgene expression. Taken together these results demonstrate that a reduction in p27 expression is sufficient to sensitize somatotropes to the proliferative actions of excess GHRH, resulting in the earlier appearance and increased penetrance of hGHRH-induced pituitary tumors.
AbstractList p27Kip1 (p27) controls cell cycle progression by binding to and inhibiting the activity of cyclin dependent kinases. Disruption of the p27 gene in mice (p27-/-) results in increased body growth with a disproportionate enlargement of the spleen, thymus, testis, ovary and pituitary. The increase in pituitary size is due to selective hyperplasia of the intermediate lobe (IL) while the anterior lobe (AL) is not overtly affected. p27 heterozygous mice (p27+/-), as well as p27-/- mice, are hypersensitive to radiation- and chemical-induced tumors compared to wildtype (p27+/+) littermates. Therefore, unlike classical tumor suppressors, only a reduction in p27 levels is necessary to predispose tissues to secondary tumor promoters. Consistent with these studies is the fact that the p27 gene sequence and mRNA levels appear normal in human pituitary adenomas while p27 protein levels are decreased. Therefore, a reduction in p27 levels could be sufficient to sensitize pituitary cells to tumorigenic factors. To test this hypothesis, metallothionein promoter-driven, human growth hormone-releasing hormone (MT-hGHRH) transgenic mice, that exhibit somatotrope hyperplasia before 9 months of age and subsequent adenoma formation with 30 - 40% penetrance, were crossbred with p27+/- mice for two successive generations to produce p27+/+, p27+/- and p27-/- mice that expressed the hGHRH transgene. At 10 - 12 weeks of age, p27-/- and p27+/+, hGHRH mice were larger than their p27+/+ littermates and displayed characteristic hyperplasia of the IL and AL, respectively. Expression of the hGHRH transgene in both p27+/- and p27-/- mice selectively expanded the population of somatotropes within the AL, where pituitaries of p27+/-, hGHRH and p27-/-, hGHRH mice were two- and fivefold larger than p27+/+, hGHRH pituitaries, respectively. There was also a synergistic effect of hGHRH transgene expression and p27-deficiency on liver, spleen and ovarian growth. At 6 - 8 months of age, 83% of p27+/-, hGHRH mice displayed macroscopic AL adenomas (>100 mg), while all pituitaries from p27+/+, hGHRH mice remained hyperplastic (<20 mg). In contrast to the dramatic effects of p27-deficiency on hGHRH-induced organ growth, elimination of p53, by crossbreeding MT-hGHRH mice to p53-deficient mice, did not augment the hyperplastic/tumorigenic effects of hGHRH transgene expression. Taken together these results demonstrate that a reduction in p27 expression is sufficient to sensitize somatotropes to the proliferative actions of excess GHRH, resulting in the earlier appearance and increased penetrance of hGHRH-induced pituitary tumors.
p27Kip1 (p27) controls cell cycle progression by binding to and inhibiting the activity of cyclin dependent kinases. Disruption of the p27 gene in mice (p27-/-) results in increased body growth with a disproportionate enlargement of the spleen, thymus, testis, ovary and pituitary. The increase in pituitary size is due to selective hyperplasia of the intermediate lobe (IL) while the anterior lobe (AL) is not overtly affected. p27 heterozygous mice (p27+/-), as well as p27-/- mice, are hypersensitive to radiation- and chemical-induced tumors compared to wildtype (p27+/+) littermates. Therefore, unlike classical tumor suppressors, only a reduction in p27 levels is necessary to predispose tissues to secondary tumor promoters. Consistent with these studies is the fact that the p27 gene sequence and mRNA levels appear normal in human pituitary adenomas while p27 protein levels are decreased. Therefore, a reduction in p27 levels could be sufficient to sensitize pituitary cells to tumorigenic factors. To test this hypothesis, metallothionein promoter-driven, human growth hormone-releasing hormone (MT-hGHRH) transgenic mice, that exhibit somatotrope hyperplasia before 9 months of age and subsequent adenoma formation with 30 - 40% penetrance, were crossbred with p27+/- mice for two successive generations to produce p27+/+, p27+/- and p27-/- mice that expressed the hGHRH transgene. At 10 - 12 weeks of age, p27-/- and p27+/+, hGHRH mice were larger than their p27+/+ littermates and displayed characteristic hyperplasia of the IL and AL, respectively. Expression of the hGHRH transgene in both p27+/- and p27-/- mice selectively expanded the population of somatotropes within the AL, where pituitaries of p27+/-, hGHRH and p27-/-, hGHRH mice were two- and fivefold larger than p27+/+, hGHRH pituitaries, respectively. There was also a synergistic effect of hGHRH transgene expression and p27-deficiency on liver, spleen and ovarian growth. At 6 - 8 months of age, 83% of p27+/-, hGHRH mice displayed macroscopic AL adenomas (&gt;100 mg), while all pituitaries from p27+/+, hGHRH mice remained hyperplastic (&lt;20 mg). In contrast to the dramatic effects of p27-deficiency on hGHRH-induced organ growth, elimination of p53, by crossbreeding MT-hGHRH mice to p53-deficient mice, did not augment the hyperplastic/tumorigenic effects of hGHRH transgene expression. Taken together these results demonstrate that a reduction in p27 expression is sufficient to sensitize somatotropes to the proliferative actions of excess GHRH, resulting in the earlier appearance and increased penetrance of hGHRH-induced pituitary tumors.
p27Kip1 (p27) controls cell cycle progression by binding to and inhibiting the activity of cyclin dependent kinases. Disruption of the p27 gene in mice (p27−/−) results in increased body growth with a disproportionate enlargement of the spleen, thymus, testis, ovary and pituitary. The increase in pituitary size is due to selective hyperplasia of the intermediate lobe (IL) while the anterior lobe (AL) is not overtly affected. p27 heterozygous mice (p27+/−), as well as p27−/− mice, are hypersensitive to radiation- and chemical-induced tumors compared to wildtype (p27+/+) littermates. Therefore, unlike classical tumor suppressors, only a reduction in p27 levels is necessary to predispose tissues to secondary tumor promoters. Consistent with these studies is the fact that the p27 gene sequence and mRNA levels appear normal in human pituitary adenomas while p27 protein levels are decreased. Therefore, a reduction in p27 levels could be sufficient to sensitize pituitary cells to tumorigenic factors. To test this hypothesis, metallothionein promoter-driven, human growth hormone-releasing hormone (MT-hGHRH) transgenic mice, that exhibit somatotrope hyperplasia before 9 months of age and subsequent adenoma formation with 30–40% penetrance, were crossbred with p27+/− mice for two successive generations to produce p27+/+, p27+/− and p27−/− mice that expressed the hGHRH transgene. At 10–12 weeks of age, p27−/− and p27+/+, hGHRH mice were larger than their p27+/+ littermates and displayed characteristic hyperplasia of the IL and AL, respectively. Expression of the hGHRH transgene in both p27+/− and p27−/− mice selectively expanded the population of somatotropes within the AL, where pituitaries of p27+/−, hGHRH and p27−/−, hGHRH mice were two- and fivefold larger than p27+/+, hGHRH pituitaries, respectively. There was also a synergistic effect of hGHRH transgene expression and p27-deficiency on liver, spleen and ovarian growth. At 6–8 months of age, 83% of p27+/−, hGHRH mice displayed macroscopic AL adenomas (>100 mg), while all pituitaries from p27+/+, hGHRH mice remained hyperplastic (<20 mg). In contrast to the dramatic effects of p27-deficiency on hGHRH-induced organ growth, elimination of p53, by crossbreeding MT-hGHRH mice to p53-deficient mice, did not augment the hyperplastic/tumorigenic effects of hGHRH transgene expression. Taken together these results demonstrate that a reduction in p27 expression is sufficient to sensitize somatotropes to the proliferative actions of excess GHRH, resulting in the earlier appearance and increased penetrance of hGHRH-induced pituitary tumors.
Audience Academic
Author PENG, X. D
CHRISTOV, K. T
TEIXEIRA, L. T
KINEMAN, R. D
FROHMAN, L. A
KIYOKAWA, H
Author_xml – sequence: 1
  givenname: L. T
  surname: TEIXEIRA
  fullname: TEIXEIRA, L. T
  organization: Department of Medicine, University of Illinois at Chicago, Chicago, Illinois, IL 60612, United States
– sequence: 2
  givenname: H
  surname: KIYOKAWA
  fullname: KIYOKAWA, H
  organization: Department of Molecular Genetics, University of Illinois at Chicago, Chicago, Illinois, IL 60612, United States
– sequence: 3
  givenname: X. D
  surname: PENG
  fullname: PENG, X. D
  organization: Department of Medicine, University of Illinois at Chicago, Chicago, Illinois, IL 60612, United States
– sequence: 4
  givenname: K. T
  surname: CHRISTOV
  fullname: CHRISTOV, K. T
  organization: Department of Surgical Oncology, University of Illinois at Chicago, Chicago, Illinois, IL 60612, United States
– sequence: 5
  givenname: L. A
  surname: FROHMAN
  fullname: FROHMAN, L. A
  organization: Department of Medicine, University of Illinois at Chicago, Chicago, Illinois, IL 60612, United States
– sequence: 6
  givenname: R. D
  surname: KINEMAN
  fullname: KINEMAN, R. D
  organization: Department of Medicine, University of Illinois at Chicago, Chicago, Illinois, IL 60612, United States
BackLink http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=1341842$$DView record in Pascal Francis
https://www.ncbi.nlm.nih.gov/pubmed/10773877$$D View this record in MEDLINE/PubMed
BookMark eNp1kl1rFDEUhoNU7LZ666UMVkQvZj35mMnkshTtigVB9Dpk87GbZSYZkxnUv-CvNmNXKlLJReDkOW_enLxn6CTEYBF6imGNgXZv8mEdg15jApQJeIBWmPG2bhrBTtAKRAO1IJScorOcDwDABZBH6BQD57TjfIV-joR_8COujXVeexumavDaVvb73m_9VCmtbW-Tmqypdil-m_bVPqahmKhTOVDZh92fSvXqevNp87r2wcy68DkOaopTiqOtxhR77xYhH0OlgqmUsaEAlSvNv6uP0UOn-myfHPdz9OXd289Xm_rm4_X7q8ubWlMioFYEOoI7JYwVnbGGUwIME6a5o8RQs2XMYlAaKNcOMwcKg3CsZRx3VjtGz9HLW93i6ets8yQHn8srexVsnLPkGBpRBljAi3_AQ5xTKN4kaRmm0LawUM__SxFOhOgouZPaqd5KH1wZi9LLvfKSQMOalreL1Poeqixjy6eUCTtf6vc16BRzTtbJMflBpR8Sg1zyIfNBlnzIYz5Kw7Oj2Xk7WPMXfhuIArw4Aipr1bukgvb5jqMMd4zQX2fpxBc
CODEN ONCNES
CitedBy_id crossref_primary_10_1210_jc_2006_2843
crossref_primary_10_1038_cddis_2015_215
crossref_primary_10_1152_ajpendo_00107_2012
crossref_primary_10_1210_endo_142_3_8005
crossref_primary_10_1203_01_pdr_0000232790_53527_c6
crossref_primary_10_1210_en_2003_0357
crossref_primary_10_1073_pnas_0509514103
crossref_primary_10_1210_js_2018_00226
crossref_primary_10_1186_1471_2407_10_541
crossref_primary_10_1210_en_2008_1482
crossref_primary_10_1080_01926230390201273
crossref_primary_10_1016_S0091_3022_03_00012_8
crossref_primary_10_1016_j_beem_2010_01_001
crossref_primary_10_1016_S1043_2760_02_00613_6
crossref_primary_10_1002_jcp_21295
crossref_primary_10_1016_S0002_9440_10_64936_X
crossref_primary_10_1016_j_mce_2017_04_019
crossref_primary_10_1006_excr_2000_5143
crossref_primary_10_1590_S0004_27302004000400006
crossref_primary_10_1210_endo_142_9_8382
crossref_primary_10_1210_me_2006_0428
crossref_primary_10_1016_j_yexcr_2003_11_014
crossref_primary_10_1074_jbc_M409080200
crossref_primary_10_1210_clinem_dgac162
Cites_doi 10.1073/pnas.68.4.820
10.1016/0092-8674(94)90257-7
10.1038/sj.onc.1201134
10.1038/sj.onc.1201516
10.1210/edrv.19.6.0350
10.1093/emboj/16.17.5334
10.1530/eje.0.1360382
10.1146/annurev.med.50.1.401
10.3181/00379727-193-3-RC1
10.1210/endo.136.9.7649093
10.1227/00006123-199604000-00027
10.1002/(SICI)1521-1878(199903)21:3<221::AID-BIES6>3.0.CO;2-J
10.1210/endo-125-2-801
10.1038/24179
10.1016/S0092-8674(00)81239-8
10.1210/edrv-14-3-269
10.1007/978-3-540-69686-5_5
10.1016/S0092-8674(00)81871-1
10.1210/endo-129-6-3274
10.1210/mend-1-2-137
10.1021/bi9903446
10.1016/S0092-8674(00)81238-6
10.1210/mend-1-4-300
10.1111/j.1478-3231.1999.tb00042.x
10.1210/endo-82-6-1125
10.1210/jcem.77.1.8100831
10.1530/eje.0.1400250
10.1038/364208a0
10.1210/endo-127-5-2149
10.1210/endo.140.9.6977
10.1007/s004280050361
10.1210/mend-2-7-606
10.1210/endo-123-1-433
10.1126/science.7624798
10.1126/science.1677216
10.1210/endo-124-1-40
10.1006/scbi.1996.0035
10.1111/j.1365-2265.1994.tb02797.x
10.1210/endo.140.1.6426
10.3109/09513599809012842
10.1126/science.272.5263.877
10.1126/science.271.5257.1861
10.1074/jbc.271.31.18337
10.1038/350074a0
10.1677/joe.0.1570337
10.1016/S1383-5742(98)00022-2
10.1210/jcem.82.9.4202
10.1210/mend.12.7.0138
10.1210/jcem.84.10.6066
10.1016/S0960-9822(00)00002-6
10.1210/mend-3-5-790
10.1038/bjc.1997.521
10.1002/(SICI)1096-9896(199901)187:1<112::AID-PATH250>3.0.CO;2-3
10.1038/315413a0
10.1101/gad.13.12.1501
10.1101/gad.12.15.2245
10.1016/0303-7207(84)90097-2
10.1210/mend-3-5-815
10.1016/S0092-8674(00)81237-4
ContentType Journal Article
Copyright 2000 INIST-CNRS
COPYRIGHT 2000 Nature Publishing Group
Copyright Nature Publishing Group Apr 6, 2000
Macmillan Publishers Limited 2000.
Copyright_xml – notice: 2000 INIST-CNRS
– notice: COPYRIGHT 2000 Nature Publishing Group
– notice: Copyright Nature Publishing Group Apr 6, 2000
– notice: Macmillan Publishers Limited 2000.
DBID IQODW
CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
3V.
7TM
7TO
7U9
7X7
7XB
88A
88E
8AO
8C1
8FD
8FE
8FH
8FI
8FJ
8FK
8G5
ABUWG
AFKRA
AZQEC
BBNVY
BENPR
BHPHI
CCPQU
DWQXO
FR3
FYUFA
GHDGH
GNUQQ
GUQSH
H94
HCIFZ
K9.
LK8
M0S
M1P
M2O
M7P
MBDVC
P64
PQEST
PQQKQ
PQUKI
Q9U
RC3
PRINS
7X8
DOI 10.1038/sj.onc.1203490
DatabaseName Pascal-Francis
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
ProQuest Central (Corporate)
Nucleic Acids Abstracts
Oncogenes and Growth Factors Abstracts
Virology and AIDS Abstracts
ProQuest Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Biology Database (Alumni Edition)
Medical Database (Alumni Edition)
ProQuest Pharma Collection
Public Health Database (Proquest)
Technology Research Database
ProQuest SciTech Collection
ProQuest Natural Science Collection
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
Research Library (Alumni Edition)
ProQuest Central (Alumni Edition)
ProQuest Central UK/Ireland
ProQuest Central Essentials
Biological Science Collection
AUTh Library subscriptions: ProQuest Central
ProQuest Natural Science Collection
ProQuest One Community College
ProQuest Central Korea
Engineering Research Database
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
Research Library Prep
AIDS and Cancer Research Abstracts
SciTech Premium Collection (Proquest) (PQ_SDU_P3)
ProQuest Health & Medical Complete (Alumni)
ProQuest Biological Science Collection
Health & Medical Collection (Alumni Edition)
PML(ProQuest Medical Library)
ProQuest Research Library
Biological Science Database
Research Library (Corporate)
Biotechnology and BioEngineering Abstracts
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central Basic
Genetics Abstracts
ProQuest Central China
MEDLINE - Academic
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
Research Library Prep
ProQuest Central Student
Oncogenes and Growth Factors Abstracts
Technology Research Database
ProQuest Central Essentials
Nucleic Acids Abstracts
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
SciTech Premium Collection
ProQuest One Community College
Research Library (Alumni Edition)
ProQuest Natural Science Collection
ProQuest Pharma Collection
ProQuest Biology Journals (Alumni Edition)
ProQuest Central
Genetics Abstracts
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
Natural Science Collection
ProQuest Central Korea
Biological Science Collection
AIDS and Cancer Research Abstracts
ProQuest Research Library
ProQuest Medical Library (Alumni)
ProQuest Public Health
Virology and AIDS Abstracts
ProQuest Biological Science Collection
ProQuest Central Basic
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
Biological Science Database
ProQuest SciTech Collection
ProQuest Hospital Collection (Alumni)
Biotechnology and BioEngineering Abstracts
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
Engineering Research Database
ProQuest One Academic
ProQuest Central (Alumni)
ProQuest Central China
MEDLINE - Academic
DatabaseTitleList MEDLINE
Research Library Prep
MEDLINE - Academic
Research Library Prep
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 3
  dbid: BENPR
  name: AUTh Library subscriptions: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Chemistry
Biology
EISSN 1476-5594
EndPage 1884
ExternalDocumentID 1012880141
A205456764
10_1038_sj_onc_1203490
10773877
1341842
Genre Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S
Journal Article
GeographicLocations United States
United States--US
Illinois
Chicago Illinois
GeographicLocations_xml – name: United States
– name: United States--US
– name: Illinois
– name: Chicago Illinois
GrantInformation_xml – fundername: NIDDK NIH HHS
  grantid: DK-30667
GroupedDBID ---
-Q-
.55
.GJ
0R~
123
29N
2WC
36B
39C
3O-
3V.
4.4
406
53G
5RE
70F
7X7
88A
88E
8AO
8C1
8FE
8FH
8FI
8FJ
8G5
8R4
8R5
AADWK
AANZL
AATNV
AAWBL
AAYFA
AAYJO
AAZLF
ABAWZ
ABDBF
ABEFU
ABGIJ
ABJNI
ABLJU
ABUWG
ACAOD
ACBMV
ACBRV
ACBYP
ACGFO
ACGFS
ACIGE
ACKTT
ACMJI
ACPRK
ACRQY
ACTTH
ACVWB
ACZOJ
ADBBV
ADFRT
ADHDB
ADMDM
ADQMX
ADYYL
AEDAW
AEFTE
AEJRE
AENEX
AEVLU
AEXYK
AFFNX
AFKRA
AFNRJ
AFSHS
AGEZK
AGGBP
AGHAI
AHMBA
AHPSJ
AHSBF
AILAN
AJCLW
AJDOV
AJRNO
ALFFA
ALMA_UNASSIGNED_HOLDINGS
AMRJV
AMYLF
ASPBG
AVWKF
AXYYD
AZFZN
AZQEC
B0M
BAWUL
BBNVY
BENPR
BHPHI
BKKNO
BPHCQ
BVXVI
CAG
CCPQU
COF
CS3
DIK
DNIVK
DPUIP
DU5
DWQXO
E3Z
EAD
EAP
EBC
EBD
EBLON
EBS
EE.
EIOEI
EJD
EMB
EMK
EMOBN
EPL
ESX
F5P
FDQFY
FEDTE
FERAY
FIZPM
FRP
FSGXE
FYUFA
GNUQQ
GUQSH
HCIFZ
HMCUK
HVGLF
HZ~
IAO
IHR
INH
INR
IQODW
ITC
IWAJR
JSO
JZLTJ
KQ8
L7B
LGEZI
LK8
LOTEE
M0L
M1P
M2O
M7P
N9A
NADUK
NAO
NQJWS
NXXTH
NYICJ
O9-
OK1
OVD
P2P
PQQKQ
PROAC
PSQYO
Q2X
RNS
RNT
RNTTT
SNX
SNYQT
SOHCF
SRMVM
SV3
SWTZT
TAOOD
TBHMF
TDRGL
TEORI
TR2
TSG
TUS
UDS
UKHRP
W2D
WH7
X7M
ZA5
ZXP
~8M
AAYZH
ABAKF
ABZZP
AEMSY
AFBBN
AGQEE
ALIPV
CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
FIGPU
7TM
7TO
7U9
7XB
8FD
8FK
FR3
H94
K9.
MBDVC
P64
PQEST
PQUKI
Q9U
RC3
PRINS
7X8
ID FETCH-LOGICAL-c3290-a208218a9de98ded73204124c7f32d3db44e10ac037cf14f0a109f464718ecf43
IEDL.DBID BENPR
ISSN 0950-9232
IngestDate Sat Oct 26 00:54:18 EDT 2024
Tue Oct 29 06:02:00 EDT 2024
Thu Oct 10 22:10:56 EDT 2024
Fri Feb 23 00:21:18 EST 2024
Tue Feb 06 05:32:57 EST 2024
Thu Sep 26 19:16:48 EDT 2024
Tue Oct 15 23:17:04 EDT 2024
Fri Feb 09 04:38:28 EST 2024
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 15
Keywords Cell proliferation
Nucleotide sequence
Enzyme
Induction
Somatotropin releasing factor
Transferases
Hyperplasia
Rodentia
Transgenic animal
Cyclin
Adenoma
Gene expression
Carcinogenesis
Signal transduction
Vertebrata
Insulin like growth factor
Mammalia
Mutagenesis
Mouse
Protein kinase
Molecular complex
Benign neoplasm
Language English
License CC BY 4.0
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c3290-a208218a9de98ded73204124c7f32d3db44e10ac037cf14f0a109f464718ecf43
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
OpenAccessLink https://doi.org/10.1038/sj.onc.1203490
PMID 10773877
PQID 227299832
PQPubID 36330
PageCount 10
ParticipantIDs proquest_miscellaneous_71059594
proquest_journals_2641306604
proquest_journals_227299832
gale_infotracmisc_A205456764
gale_infotracacademiconefile_A205456764
crossref_primary_10_1038_sj_onc_1203490
pubmed_primary_10773877
pascalfrancis_primary_1341842
PublicationCentury 2000
PublicationDate 2000-Apr-06
PublicationDateYYYYMMDD 2000-04-06
PublicationDate_xml – month: 04
  year: 2000
  text: 2000-Apr-06
  day: 06
PublicationDecade 2000
PublicationPlace Basingstoke
PublicationPlace_xml – name: Basingstoke
– name: England
– name: New York
PublicationTitle Oncogene
PublicationTitleAlternate Oncogene
PublicationYear 2000
Publisher Nature Publishing
Nature Publishing Group
Publisher_xml – name: Nature Publishing
– name: Nature Publishing Group
References BF1203490_CR1
BF1203490_CR2
BF1203490_CR49
BF1203490_CR5
BF1203490_CR6
BF1203490_CR3
BF1203490_CR4
BF1203490_CR9
BF1203490_CR7
BF1203490_CR8
BF1203490_CR40
BF1203490_CR48
BF1203490_CR47
BF1203490_CR46
BF1203490_CR45
BF1203490_CR44
BF1203490_CR43
BF1203490_CR42
BF1203490_CR41
BF1203490_CR19
BF1203490_CR18
BF1203490_CR17
BF1203490_CR16
BF1203490_CR51
BF1203490_CR50
BF1203490_CR15
BF1203490_CR59
BF1203490_CR14
BF1203490_CR58
BF1203490_CR13
BF1203490_CR57
BF1203490_CR12
BF1203490_CR56
BF1203490_CR11
BF1203490_CR55
BF1203490_CR10
BF1203490_CR54
BF1203490_CR53
BF1203490_CR52
BF1203490_CR29
BF1203490_CR28
BF1203490_CR27
BF1203490_CR62
BF1203490_CR61
BF1203490_CR60
BF1203490_CR26
BF1203490_CR25
BF1203490_CR24
BF1203490_CR68
BF1203490_CR23
BF1203490_CR67
BF1203490_CR22
BF1203490_CR66
BF1203490_CR21
BF1203490_CR65
BF1203490_CR20
BF1203490_CR64
BF1203490_CR63
BF1203490_CR39
BF1203490_CR38
BF1203490_CR37
BF1203490_CR36
BF1203490_CR35
BF1203490_CR34
BF1203490_CR33
BF1203490_CR32
BF1203490_CR31
BF1203490_CR30
References_xml – ident: BF1203490_CR34
  doi: 10.1073/pnas.68.4.820
– ident: BF1203490_CR32
  doi: 10.1016/0092-8674(94)90257-7
– ident: BF1203490_CR42
  doi: 10.1038/sj.onc.1201134
– ident: BF1203490_CR15
  doi: 10.1038/sj.onc.1201516
– ident: BF1203490_CR1
  doi: 10.1210/edrv.19.6.0350
– ident: BF1203490_CR40
– ident: BF1203490_CR8
– ident: BF1203490_CR67
  doi: 10.1093/emboj/16.17.5334
– ident: BF1203490_CR23
  doi: 10.1530/eje.0.1360382
– ident: BF1203490_CR66
  doi: 10.1146/annurev.med.50.1.401
– ident: BF1203490_CR2
  doi: 10.3181/00379727-193-3-RC1
– ident: BF1203490_CR61
  doi: 10.1210/endo.136.9.7649093
– ident: BF1203490_CR64
  doi: 10.1227/00006123-199604000-00027
– ident: BF1203490_CR35
  doi: 10.1002/(SICI)1521-1878(199903)21:3<221::AID-BIES6>3.0.CO;2-J
– ident: BF1203490_CR9
  doi: 10.1210/endo-125-2-801
– ident: BF1203490_CR19
  doi: 10.1038/24179
– ident: BF1203490_CR20
  doi: 10.1016/S0092-8674(00)81239-8
– ident: BF1203490_CR46
  doi: 10.1210/edrv-14-3-269
– ident: BF1203490_CR60
  doi: 10.1007/978-3-540-69686-5_5
– ident: BF1203490_CR36
  doi: 10.1016/S0092-8674(00)81871-1
– ident: BF1203490_CR7
– ident: BF1203490_CR10
  doi: 10.1210/endo-129-6-3274
– ident: BF1203490_CR5
  doi: 10.1210/mend-1-2-137
– ident: BF1203490_CR68
  doi: 10.1021/bi9903446
– ident: BF1203490_CR33
  doi: 10.1016/S0092-8674(00)81238-6
– ident: BF1203490_CR6
  doi: 10.1210/mend-1-4-300
– ident: BF1203490_CR59
  doi: 10.1111/j.1478-3231.1999.tb00042.x
– ident: BF1203490_CR21
  doi: 10.1210/endo-82-6-1125
– ident: BF1203490_CR28
  doi: 10.1210/jcem.77.1.8100831
– ident: BF1203490_CR3
  doi: 10.1530/eje.0.1400250
– ident: BF1203490_CR39
  doi: 10.1038/364208a0
– ident: BF1203490_CR22
  doi: 10.1210/endo-127-5-2149
– ident: BF1203490_CR47
  doi: 10.1210/endo.140.9.6977
– ident: BF1203490_CR4
  doi: 10.1007/s004280050361
– ident: BF1203490_CR44
  doi: 10.1210/mend-2-7-606
– ident: BF1203490_CR49
– ident: BF1203490_CR43
  doi: 10.1210/endo-123-1-433
– ident: BF1203490_CR51
  doi: 10.1126/science.7624798
– ident: BF1203490_CR12
  doi: 10.1126/science.1677216
– ident: BF1203490_CR53
  doi: 10.1210/endo-124-1-40
– ident: BF1203490_CR17
  doi: 10.1006/scbi.1996.0035
– ident: BF1203490_CR37
  doi: 10.1111/j.1365-2265.1994.tb02797.x
– ident: BF1203490_CR45
  doi: 10.1210/endo.140.1.6426
– ident: BF1203490_CR56
  doi: 10.3109/09513599809012842
– ident: BF1203490_CR65
– ident: BF1203490_CR13
  doi: 10.1126/science.272.5263.877
– ident: BF1203490_CR26
  doi: 10.1126/science.271.5257.1861
– ident: BF1203490_CR54
  doi: 10.1074/jbc.271.31.18337
– ident: BF1203490_CR11
  doi: 10.1038/350074a0
– ident: BF1203490_CR62
  doi: 10.1677/joe.0.1570337
– ident: BF1203490_CR58
– ident: BF1203490_CR31
– ident: BF1203490_CR27
  doi: 10.1016/S1383-5742(98)00022-2
– ident: BF1203490_CR63
  doi: 10.1210/jcem.82.9.4202
– ident: BF1203490_CR55
  doi: 10.1210/mend.12.7.0138
– ident: BF1203490_CR38
  doi: 10.1210/jcem.84.10.6066
– ident: BF1203490_CR48
– ident: BF1203490_CR30
  doi: 10.1016/S0960-9822(00)00002-6
– ident: BF1203490_CR14
  doi: 10.1210/mend-3-5-790
– ident: BF1203490_CR29
  doi: 10.1038/bjc.1997.521
– ident: BF1203490_CR52
  doi: 10.1002/(SICI)1096-9896(199901)187:1<112::AID-PATH250>3.0.CO;2-3
– ident: BF1203490_CR24
  doi: 10.1038/315413a0
– ident: BF1203490_CR41
– ident: BF1203490_CR57
  doi: 10.1101/gad.13.12.1501
– ident: BF1203490_CR18
  doi: 10.1101/gad.12.15.2245
– ident: BF1203490_CR25
  doi: 10.1016/0303-7207(84)90097-2
– ident: BF1203490_CR16
  doi: 10.1210/mend-3-5-815
– ident: BF1203490_CR50
  doi: 10.1016/S0092-8674(00)81237-4
SSID ssj0007902
Score 1.6417296
Snippet p27Kip1 (p27) controls cell cycle progression by binding to and inhibiting the activity of cyclin dependent kinases. Disruption of the p27 gene in mice...
SourceID proquest
gale
crossref
pubmed
pascalfrancis
SourceType Aggregation Database
Index Database
StartPage 1875
SubjectTerms Adenoma
Adenoma - genetics
Age
Age Factors
Animals
Biological and medical sciences
Brain tumors
Cell cycle
Cell Cycle Proteins
Cell physiology
Cell transformation and carcinogenesis. Action of oncogenes and antioncogenes
Cross-breeding
Cyclin-Dependent Kinase Inhibitor p27
Cyclin-Dependent Kinases - antagonists & inhibitors
Fundamental and applied biological sciences. Psychology
Genes
Genes, Tumor Suppressor
Genetic aspects
Growth hormone-releasing hormone
Growth Hormone-Releasing Hormone - pharmacology
Growth hormones
Humans
Hyperplasia
Hypotheses
Kinases
Liver - pathology
Metallothionein
Mice
Mice, Transgenic
Microtubule-Associated Proteins - genetics
Microtubule-Associated Proteins - metabolism
Molecular and cellular biology
mRNA
Ovaries
p27 gene
p53 Protein
Physiological aspects
Pituitary
Pituitary Gland - pathology
Pituitary Neoplasms - genetics
Risk factors
Somatotropin
Somatotropin releasing hormone
Spleen
Spleen - pathology
Thymus gland
Transgenic mice
Tumor Suppressor Proteins
Tumors
Title p27Kip1-deficient mice exhibit accelerated growth hormone-releasing hormone (GHRH)-induced somatotrope proliferation and adenoma formation
URI https://www.ncbi.nlm.nih.gov/pubmed/10773877
https://www.proquest.com/docview/227299832
https://www.proquest.com/docview/2641306604
https://search.proquest.com/docview/71059594
Volume 19
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3LbtQwFLXoVDwkhGB4DX3gBRKwcOvYjp2sUBm1jEBUqKLS7CyPH7RdJKFJF_wCX8114gyMBGyyiC07ybXvOdd27kHoVSbB5eWmJBlwcSK4MKTIpCGADhbQxQvu-tMWp3JxLj4u82VacGvTscrRJ_aO2tU2rpEfAnCDu5WSinfNdxJVo-LuapLQ2ELbDCIFNkHb749Pv5ytfbEaTh0Cj6AEqAwb0zby4rC9OqhhCmYsZmihG7CUnPP9xrTwocKgcPFvCtpD0clD9CBxSHw0GP0RuuWrKbo9qEr-mKK781HEbYrufE5754_Rz4apT5dNRpyPWSMAbHCUosc-SmRfdthYCxAUM0c4_A2C8-4CXwChrStPorCKiYsK4x385sPibPGWQEAPQ8PhtgbiW3dxYR83UQco-GFkYVM5bMC3QQW8_lHyCTo_Of46X5CkxEAsZyUlhgFTyApTOl8WzjvFWS9bbVXgzHG3EsJn1FjKlQ2ZCNRktAxCRuTzNgj-FE0qeLrnCHvLcmg0KCed8DQ3oqCrwnppcx9s4DP0ejSEboaEG7rfKOeFbq80mEwnk0HNaCcdZ2J3baxJPxRAPzGnlT5iNNJDJcUM7W7UBBvYjeK9DUv_7hcgvhBshnZGy-s0w1vNGIQlJfhDaPwvpevROkMv18Wx33imrfL1TatVpLZ5CTWeDaPpj_dVihdKvfh_0zvo3pAYQBAqd9Gku77xe0CRutU-2lJLBddinu2nOfEL9GURNw
link.rule.ids 315,783,787,12070,12237,21402,27938,27939,31733,31734,33280,33281,33758,33759,43324,43593,43819,74081,74350,74638
linkProvider ProQuest
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3LbtQwFLWgCIqEEAyvoS31AglYmDq2EycrVFWUQB8L1Eqzszx-0HaRhCZd8At8NffmMTASsB1bdibXvuf4kXMIeZ1kkPJSW7AEuDhTUlmWJ5llgA4O0CUo6fvbFqdZea6-LNLFuOHWjtcqp5zYJ2pfO9wj3wPghnSbZVx9aL4zdI3C09XRQuM2uYM6XKidrxerBRfXw51DYBGcAZERk2ijzPfaq_c1TMBEoD4LXwOlMTU_aGwLrykO_hb_JqA9EB0-Ig9HBkn3h5A_JrdCNSN3B0_JHzOyeTBZuM3IvZPx5PwJ-dkIfXTZJMwH1IwAqKFoRE8DGmRfdtQ6BwCEuhGefoOleXdBL4DO1lVgaKticUth-oW-_VR-Ld8xWM7DwPC0rYH21h1u69MGXYBiGMYVtZWnFjIbVKCrzySfkvPDj2cHJRt9GJiTouDMCuAJSW4LH4rcB6-l6E2rnY5SeOmXSoWEW8eldjFRkduEF1FliHvBRSWfkY0Knu4FocGJFBqN2mdeBZ5alfNl7kLm0hBdlHPyZgqEaQa5DdMfk8vctFcGQmbGkEFNjJPBedhdW2fHzwmgH1S0MvuCIznUmZqT7bWaEAO3VryzFunf_QLA50rMydYUeTPO79YIAYuSArIhNP6X0tVYnZPdVTH2izfaqlDftEYjsU0LqPF8GE1__F-tZa71y_83vUs2y7OTY3P8-fRoi9wfJAIU49k22eiub8IOkKVu-aqfEb8Akr8RDg
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Nb9QwELWgiIKEECxfS1vqAxJwMOvYTuycULWwLBQqhKjUm-X1B20PSWjSA3-BX804cbasBFzXlp3NeOY925N5CD3PCgh5uSlJBlycCC4MUVlhCKCDBXTxgrs-2-KoWB6Ljyf5Scp_alNa5RgT-0DtahvPyGcA3BBui4KKWUhpEV_eLt40P0hUkIo3rUlO4zq6AaiYRxkHNb9K95BD_iEwCkqA1LCxgCNXs_b8dQ3OmLFYq4VuAFQK03ca08IrC4PWxb_JaA9Ki3vobmKT-GAw_310zVcTdHPQl_w5Qbfmo5zbBG1_TrfoD9CvhsnDsyYjzsf6EQA7OIrSYx_Fss86bKwFMIo1JBz-Dtv07hSfArWtK0-ixIqJxwvjL_jl--XX5SsCW3tYJA63NVDguotH_LiJikDBD2sMm8phA1EOOuD1J5MP0fHi3bf5kiRNBmI5KykxDDhDpkzpfKmcd5KzXsDaysCZ424lhM-osZRLGzIRqMloGUQRMdDbIPgjtFXB0z1B2FuWw6BBusIJT3MjFF0p6wub-2ADn6IXoyF0M5Te0P2VOVe6PddgMp1MBj2jnXT0ye7CWJM-LYB5YnUrfcBoJIqyEFO0u9ETbGA3mvc2LH01L4C9EmyKdkbL6-TrrWYMNiglREYY_C-t63U7Rfvr5jhvzG6rfH3ZahlJbl5Cj8fDavrj_0rJlZRP_z_0PtoGZ9CfPhwd7qDbQ7UAQWixi7a6i0u_B7ypWz3rHeI3G4wVDg
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=p27Kip1-deficient+mice+exhibit+accelerated+growth+hormone-releasing+hormone+-induced+somatotrope+proliferation+and+adenoma+formation&rft.jtitle=Oncogene&rft.au=Teixeira%2C+L+T&rft.au=Kiyokawa%2C+H&rft.au=Peng%2C+X+D&rft.au=Christov%2C+K+T&rft.date=2000-04-06&rft.pub=Nature+Publishing+Group&rft.issn=0950-9232&rft.eissn=1476-5594&rft.volume=19&rft.issue=15&rft.spage=1875&rft_id=info:doi/10.1038%2Fsj.onc.1203490&rft.externalDocID=A205456764
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0950-9232&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0950-9232&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0950-9232&client=summon